Promising cancer combo trial halted after just 2 patients
NCT ID NCT07040059
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This early-stage trial tested a new drug called AUR103 calcium, given together with standard treatments (trastuzumab and chemotherapy), for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The study was planned in two parts, but was terminated early after enrolling only 2 participants, so no meaningful conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asha Hospital and Research Centre
Bangalore, Karnataka, 560076, India
-
HCG Cancer Center
Vizag, Andhra Pradesh, 530040, India
-
Hope & Heal Cancer Hospital and Research Center
Siliguri, West Bengal, 734015, India
-
Karnataka Cancer Hospital and Radiation Theraphy Center
Bangalore, Karnataka, 560096, India
-
Kiran Hospital Multi Super Speciality Hospital & Reseach Center
Surat, Gujarat, 395004, India
-
Netaji Subhas Chandra Bose Cancer Hospital
Kolkata, West Bengal, 700094, India
-
Shalby Hospital
Ahmedabad, Gujarat, 380015, India
-
The Gujarat Cancer & Research Insititute
Ahmedabad, Gujarat, 380016, India
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AUR103 calcium (given with trastuzumab and chemotherapy)
What this could lead to
If it worked, this could point toward a new combination treatment for advanced HER2-positive stomach cancer.
What could go wrong
The trial was terminated early with only 2 participants, so there is very little data. It is too early to know if the drug is safe or effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.